AUTHORS
Feifei Tang, MD, PhD, Xinyi Qi2, Xiaosu Zhao3, Qian Jiang Jr, MD4, Hao Jiang5, Lanping Xu, MD6, Xiaohui Zhang, MD, PhD7
AFFILIATIONS
1 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
2 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
3 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
4 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
5 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
6 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
7 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
ABSTRACT
Background
Relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) typically carries a poor prognosis. Although gilteritinib improves survival compared with salvage chemotherapy, responses are often neither deep nor durable, prompting its combination with venetoclax and azacitidine (GVA) or intensive chemotherapy (GIC). However, real-world data directly comparing the clinical outcomes and safety profiles of these two combination regimens in R/R cohorts remain scarce.
Aim
We aimed to compare the clinical characteristics, treatment efficacy, safety, and prognosis of GVA and GIC in patients with R/R FLT3-mutated AML in a real-world cohort in China.
Methods
We analyzed the baseline characteristics and clinical outcomes of 91 patients with R/R FLT3-mutated AML, including 71 patients treated with GVA and 20 treated with GIC. We evaluated and compared treatment response, measurable residual disease (MRD) response, hematologic recovery, allogeneic hematopoietic stem cell transplantation (allo-HSCT) outcomes, early mortality, overall survival (OS), and disease-free survival (DFS) between the two cohorts.
Results
A total of 91 patients with relapsed/refractory FLT3-mutated AML were included, of whom 71 received GVA and 20 received GIC. GVA had similar mCRc (CR+CRi+MLFS), 1-year OS, and 1-year DFS compared to GIC (mCRc: 70.4% vs. 75.0%, P=0.790; OS: 70.4% vs. 70.0%, P=0.276; DFS: 55.5% vs. 76.5%, P=0.267). Among 84 patients with evaluable FLT3-MRD data, the rate of FLT3-MRD negativity after cycle 2 was similar between the GVA and GIC groups (42.4% vs. 55.6%, P=0.450). Among 45 patients with evaluable hematologic recovery data, there were no significant differences between the GVA and GIC groups in the median time to ANC recovery (41.0 vs. 41.5 days, P=0.832) and platelet recovery (24.0 vs. 35.0 days, P=0.345). In the GVA group, GATA2 and IDH1 mutations were independently associated with inferior OS (GATA2: HR=6.22, 95% CI 1.41–27.55, P=0.016; IDH1: HR=3.77, 95% CI 1.06–13.37, P=0.040). Patients with a non-FLT3 mutation burden ≥3 had inferior 1-year OS (67.9% vs. 72.1%, P=0.031) and DFS (42.0% vs. 64.9%, P=0.027) in the GVA group. The VEN-adverse genotype (RAS-pathway/TP53 mutations) predicted inferior 1-year DFS (40.0% vs. 62.8%, P=0.039), while NPM1 plus RAS-pathway co-mutations predicted inferior 1-year OS (50.0% vs. 72.3%, P=0.048) in this cohort. In the GIC group, bone marrow blasts ≥30% (42.9% vs. 84.6%, P=0.037), WBC ≥15 × 10?/L (33.3% vs. 85.7%, P=0.026), and MLL-PTD (0.0% vs. 73.7%, P=0.039) predicted inferior 1-year OS, whereas tumor-suppressor pathway alterations (TP53, WT1, or PHF6) and WT1 mutations predicted inferior 1-year DFS (50.0% vs. 84.6% and 33.3% vs. 85.7%, respectively; P=0.021). In multivariate analysis, GATA2 and IDH1 mutations predicted inferior OS in the GVA group (GATA2: HR 6.22, P=0.016; IDH1: HR 3.77, P=0.040), whereas allo-HSCT predicted improved OS and DFS (OS: HR 0.17, P<0.001; DFS: HR 0.28, P<0.001).
Conclusion
GVA and GIC achieved comparable mCRc and survival outcomes in patients with R/R FLT3-mutated AML. However, distinct baseline clinical and mutational profiles dictated the differential efficacy of each regimen. Specifically, GIC may be more suitable for patients harboring the venetoclax-adverse genotype or a non-FLT3 mutation burden ≥3, whereas patients with tumor-suppressor pathway alterations may derive a greater DFS benefit from GVA.
DISCLOSURES
Xinyi Qi: No relevant conflicts of interest to declare.